Clinical Trial Update: Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating MGCND00EP1 as an add-on therapy for resistant epilepsy in children and adolescents has been withdrawn. No results are reported in the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• MGCND00EP1

Snippet

Sponsor: MGC Pharmaceuticals d.o.o | Conditions: Resistant Epilepsy, Drug, Adolescent Epilepsy | Phase 2 | Status: WITHDRAWN